Recommend Human Vaccines to your librarian for 2008. Download form here.

Sign up for TOC Alerts

Email this page

Print this page

Research Paper

Post-Marketing Safety Monitoring of a New Group B Meningococcal Vaccine in New Zealand, 2004-2006

Anne McNicholas, Yvonne Galloway, Paul Stehr-Green, Stewart Reid, Sarah Radke, Kerry Sexton, Charlotte Kieft, Claire Macdonald, Jocelyn Neutze, Ross Drake, Dorothy Isaac, Mary O'Donnell, Michael Tatley, Philipp Oster and Jane O'Hallahan

This is an open-access article

 Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.

New Zealand introduced a new outer membrane vesicle vaccine in 2004 to combat an epidemic of group B meningococcal disease. An Independent Safety Monitoring Board oversaw intensive safety monitoring, which included hospital surveillance, health professional reporting (passive and active) and mortality monitoring. With over three million doses administered to individuals aged under 20 years, the monitoring results provide consistent evidence supporting the vaccine’s safety.

Authors

Anne McNicholas

Meningococcal Vaccine Strategy, Ministry of Health, Wellington, New Zealand

Yvonne Galloway

Meningococcal Vaccine Strategy, Ministry of Health, Wellington, New Zealand

Paul Stehr-Green

Meningococcal Vaccine Strategy, Ministry of Health, Wellington, New Zealand

Stewart Reid

Meningococcal Vaccine Strategy, Ministry of Health, Wellington, New Zealand

Sarah Radke

Meningococcal Vaccine Strategy, Ministry of Health, Wellington, New Zealand

Kerry Sexton

Meningococcal Vaccine Strategy, Ministry of Health, Wellington, New Zealand

Charlotte Kieft

Meningococcal Vaccine Strategy, Ministry of Health, Wellington, New Zealand

Claire Macdonald

Meningococcal Vaccine Strategy, Ministry of Health, Wellington, New Zealand

Jocelyn Neutze

Middlemore Hospital, Manukau, New Zealand

Ross Drake

Auckland City Hospital, Auckland, New Zealand

Dorothy Isaac

Middlemore Hospital, Manukau, New Zealand

Mary O'Donnell

Auckland City Hospital, Auckland, New Zealand

Michael Tatley

Centre for Adverse Reactions Monitoring, University of Otago, Dunedin, New Zealand

Philipp Oster

Novartis Vaccines and Diagnostics S.r.l., Siena, Italy

Jane O'Hallahan

Meningococcal Vaccine Strategy, Ministry of Health, Wellington, New Zealand

This is an open-access article

 Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.